Malignancy risk of non‐biologic immunosuppressive therapies: A review of the literature with evidence‐based treatment recommendations
Sign Up to like & getrecommendations! Published in 2022 at "Experimental Dermatology"
DOI: 10.1111/exd.14647
Abstract: Non‐biologic immunosuppressive therapies are a mainstay in the treatment of various dermatologic conditions. However, the use of these therapies has been scrutinized for potentially increasing risk of haematologic or solid‐organ malignancies. Currently, there are no… read more here.
Keywords: non biologic; biologic immunosuppressive; malignancy; risk ... See more keywords
THU0116 COMPARATIVE SAFETY OF BIOLOGIC DMARDS AND ABATACEPT IN RHEUMATOID ARTHRITIS WITH COPD: A REAL-WORLD POPULATION-BASED OBSERVATIONAL STUDY
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.1607
Abstract: Background The biologic DMARD abatacept has been associated with respiratory adverse events in patients with RA who have chronic obstructive pulmonary disease (COPD) in the ASSURE trial (NCT00048932), based on only 54 patients with RA… read more here.
Keywords: non biologic; biologic dmards; biologic; biologic dmard ... See more keywords